Phreesia is no longer asking the market to fund growth. The company is asking investors to believe a newly profitable patient-intake platform can keep expanding cash earnings after it slowed subscription pricing and cut a large contractor-heavy workforce. That is the entire debate. Adjusted earnings before interest, taxes, depreciation, and amortization reached $33 million in the July quarter, a margin print that outran the top line and is the first clean evidence that the May cost reset is landing in reported results.
The mix underneath is less comforting. Subscription and related services declined to $53 million as management eased pricing to keep cash-strapped provider clients on the platform. Payment solutions rose to $38 million on the AccessOne patient-financing book closed last November. Network solutions still grew, but finance leadership now flags more variability in that line for the back half of the year. The equity is therefore being asked to pay for a payments-and-ads compounder at a moment when the original software franchise is being used as a customer-retention tool rather than a price-taking engine.
Revenue rose 10 percent. Cash from operations stayed positive for a ninth straight quarter. More than $23 million of debt principal came off the revolver. Management left the full-year revenue and adjusted-EBITDA ranges unchanged. The question for the next several quarters is whether AccessOne and ProviderConnect can replace the growth that subscription pricing and life-sciences visibility no longer supply.